Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I

We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many benefits of precision radiopharmaceutical therapies to patients with cancer, in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. The combined company will have a pro forma enterprise value of approximately $640 million, and is supported by a $165 million common stock PIPE led by RA Capital Management as well as an investment from Johnson & Johnson Innovation – JJDC, Inc., Surveyor Capital (a Citadel company), Farallon Capital Management, L.L.C., BVF Partners L.P., Boxer Capital, Sphera Healthcare, Woodline Partners LP, Suvretta Capital, Fairmount Funds, and Perceptive Advisors. Upon closing, expected to be mid-year 2021, the combined company will be renamed POINT Biopharma Global Inc. and is expected to be listed on the Nasdaq Capital Market under the new ticker symbol “PNT.”

This transaction was highlighted by several media outlets including:

The team was led by Bass, Berry & Sims attorney Jay Knight and included corporate attorneys Jonathan Stanley, Susan Sidwell, Tatjana Paterno, Andrew Hard, Lauren Brown, James Litzow, Lora Wuerdeman, Mary Lindsey Hannahan and Dixon Babb; Curtis Capeling, Shelley Thomas, Shu Chen and Caitlin Wilkinson (intellectual property); Clint Hermes, Amy Morgan and Angelique Salib (healthcare); Bryan Metcalf (tax and executive compensation); Doug Dahl, Curtis Fisher and Brett Good (employee benefits); Lymari Cromwell (labor and employment); and Lucas Smith (antitrust).

Public and private companies of all sizes across a variety of industries turn to Bass, Berry & Sims for counsel on a wide range of corporate matters, including mergers, acquisitions and dispositions; capital markets transactions; executive compensation issues; corporate governance; and shareholder activism. We serve as corporate and securities counsel to more than 35 public companies and have counseled on 150 deals ranging in size from $20 million to more than $15 billion over the past two years. Our attorneys have been consistently recognized in leading industry outlets, including Chambers USA – ranked as a top corporate firm in Tennessee since 2003 – and most recently as a M&A Advisor Award recipient for – “Healthcare and Life Sciences Deal of the Year (Over $1B)” and Corporate/Strategic Deal of the Year (Over $1B) in 2020; and “Industrials Deals of the Year (Over $1B)” in 2019. Click here to learn more.

You Also May Be Interested In: